Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imidazoline receptor effectors (benzimidazole derivatives)
- Development stage
- Preclinical
- Lead developer
- nanoigel
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Subcutaneous
01
Overview
Imidazoline receptor effectors (benzimidazole derivatives) are a class of small molecule compounds developed by nanoigel that function as agonists of the imidazoline I2 receptor. These compounds are being explored for their potential in geroprotection (anti-aging), as well as for managing arterial hypertension and hypoglycemia. The program is currently in the preclinical stage of development, with the underlying technology described in patent WO2021145785A1. The I2 receptor is a non-adrenergic binding site involved in various physiological processes, and its modulation is proposed to offer therapeutic benefits in metabolic and cardiovascular conditions.
- Other names
- I2 imidazoline receptor agonistsI-2 imidazoline receptor agonistsI 2 imidazoline receptor agonistsbenzimidazole derivativesimidazoline receptor effectors
02
Targets
CKB (Creatine kinase B-type)I2R (Imidazoline I2 receptor)ADRA2A (α2A)MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on imidazoline receptor effectors (benzimidazole derivatives).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imidazoline receptor effectors (benzimidazole derivatives).